A Phase 1/2 Trial of Amplimexon® (Imexon, Inj.) for Patients With Previously Treated Multiple Myeloma
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Determine the maximally tolerated dose of imexon in multiple myeloma patients
United States: Food and Drug Administration
AMP-007
NCT00327249
October 2005
January 2008
Name | Location |
---|---|
Investigational Site 025 | Little Rock, Arkansas 72206 |
Investigational Site 008 | Houston, Texas 77030 |